Chronic hand eczema is a type of skin disease that affects the skin on your hands and wrists. While there is no cure for chronic hand eczema, different types of medicines can be used to help manage ...

Please provide your email address to receive an email when new articles are posted on . Anzupgo (delgocitinib) cream 20 mg/g is a steroid-free JAK inhibitor. Data from the DELTA trials demonstrated ...

In Phase 3 clinical trials, patients experienced significant skin clearance along with marked relief from pain and itch; the trials revealed a favorable safety profile compared to cream vehicle. 4,5,6 ...

Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic hand eczema (CHE). The launch of pan-JAK inhibitor Anzupgo (delgocitinib) ...

A chronic form of eczema that develops specifically in the hands now has its first approved FDA-approved drug, a topical cream from dermatological medicines specialist LEO Pharma. The Wednesday ...

LEO Pharma is seeking to expand the availability of Anzupgo ® (delgocitinib) cream to China, as the company announces the submission of a New Drug Application (NDA) to the National Medical Products ...

The campaign focuses on educating the one in 10 U.S. adults living with chronic hand eczema (CHE), particularly the one in three patients who have never heard the specific name of their condition.

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect. The EMA's ...

Europe's Committee for Medicinal Products for Human Use (CHMP) recommended the granting of marketing authorization for Anzupgo (delgocitinib; LEO Pharma) to treat moderate to severe chronic hand ...

Credit: LEO Pharma. Delgocitinib is a JAK inhibitor that blocks the activation of the JAK-STAT pathway which has been shown to play a key role in the pathophysiology of chronic inflammatory skin ...